What Makes Tianming Pharmaceutical Group Stand Out in 2026

A Full-Chain Partner for Pharmaceutical Intermediates

In a global active pharmaceutical ingredient (API) market that reached USD 226.1 billion in 2024 with 5.3% year-over-year growth and is projected to reach USD 384.5 billion by 2033, sourcing reliable intermediates and APIs has become a strategic concern for pharmaceutical companies worldwide. China accounts for approximately 30% of global API production capacity, and within this landscape, Shandong Tianming Pharmaceutical Group has built a position as an R&D-driven pharmaceutical raw material and intermediate enterprise operating an integrated R&D-production model. Headquartered in Jinan, Shandong Province, the group—commonly known by its brand name Tianming Pharmaceutical—provides API, intermediates, and CMO/CDMO custom development and production solutions to customers across China and more than 30 countries and regions spanning South Asia, Southeast Asia, the Middle East, Central and South America, and Africa.

From a Single Enterprise to an Integrated Group

Tianming Pharmaceutical Group’s roots trace back to 2010, when its predecessor, Shandong Sihuan Pharmaceutical Co., Ltd., was established. Over the following decade, the company expanded steadily: a Jinan R&D entity became operational in 2015, an India Delhi branch was established in 2017, Guangxi Tianming Pharmaceutical Co., Ltd. was founded in 2018, and Jining Tianming Pharmaceutical Co., Ltd. followed in 2019. In 2020, Shandong Tianming Pharmaceutical Group was formally established, coordinating what has grown into two R&D centers, three domestic production bases, and two overseas business entities in India and Bangladesh. This evolution reflects a broader industry pain point that Tianming Pharmaceutical has sought to address: extended supply lead times for high-end specialty intermediates, volatile raw material pricing, inconsistent batch quality, and fragmented sourcing across multiple suppliers that raises procurement costs.

Differentiated Value Proposition

Full-Chain Product Matrix

One of the defining characteristics of Tianming Pharmaceutical is its full-chain product matrix covering intermediates from N-1 to N-5 for flagship molecules, including Sacubitril Valsartan Sodium, Orforglipron, and Finerenone. Rather than requiring customers to coordinate purchases across multiple suppliers for different stages of a synthesis route, the company offers one-stop supply of intermediates and API from gram-level to ton-level, spanning laboratory small-batch work, pilot scale-up, and commercial production.

Registration-Grade Quality Standards

Quality specifications at Tianming Pharmaceutical are described as exceeding industry norms. For example, Sacubitril Calcium is produced with individual impurity below 0.1% and chiral purity above 99.5%, while Orforglipron intermediates carry total impurities below 0.5% and enantiomer below 0.1%. These specifications are supported by complete technical documentation—including COA, MOA methodology, impurity profile studies, and stability data—that customers can use to support DMF and CEP global regulatory filings.

R&D Investment Above Industry Average

Tianming Pharmaceutical dedicates more than 10% of annual revenue to R&D innovation, compared with an industry average of around 5%, with an additional 1% of revenue allocated to management system iteration. This investment supports independent process development, such as the full-chain intermediates for Orforglipron and the Sacubitril series, and is backed by 20 invention patents and 40 utility model patents held across the group.

Scale and Capacity

The group operates three coordinated production bases with more than 160 reactor vessels and annual production capacity in the hundreds of tons. Its two R&D centers, located in Jinan and Nanjing, occupy more than 6,000 square meters of laboratory space and are staffed by an R&D team exceeding 100 personnel. A CRM plus ERP plus BPM digital management system supports rapid domestic order confirmation and full international logistics chain services, including customs clearance and trade insurance support for cross-border orders.

Flagship Product Families

Orforglipron Full-Chain Intermediates

Orforglipron, an oral non-peptide small molecule GLP-1 receptor agonist that has entered Phase III clinical trials, is supported by a full-chain intermediate matrix from starting material to advanced intermediate to API, along with impurity standards for quality analysis reference. This addresses the needs of innovator companies and CMO/CDMO partners facing requirements on quality, capacity, and cost for Phase III clinical supply and global inventory buildup, as well as advanced generic companies preparing non-infringing synthetic routes ahead of patent expiry.

Sacubitril Valsartan Sodium and Intermediates Series

Sacubitril Valsartan Sodium (LCZ696), described in the source materials as the inaugural angiotensin receptor neprilysin inhibitor (ARNI) for heart failure treatment, anchors a second flagship series. With the U.S. core patent having expired in July 2023 and the China compound patent set to expire in 2026, generic drug companies face a defined window for R&D, regulatory filing, and pre-launch inventory. Tianming Pharmaceutical’s series covers starting materials through advanced intermediates to the co-crystal API, with strict monitoring of the Sacubitril-to-Valsartan molar ratio, chiral impurities, residual solvents, particle size, and crystal form, and includes Sacubitril Calcium as a building block that can also support independent NCE development such as Sacubitril Alisartan Calcium.

A Broad Portfolio Across Therapeutic Areas

Beyond its two flagship families, Tianming Pharmaceutical’s catalog spans cardiovascular, anti-infective, anti-diabetic, anti-tumor, and nervous system intermediates, along with nicotine products and cosmetic and food ingredient raw materials such as PQQ disodium salt and beta-nicotinamide mononucleotide. This breadth allows the company to serve pharmaceutical companies, CRO/CDMO institutions, biochemical companies, trading companies, cosmetic raw material manufacturers, and health supplement producers from a single supplier relationship.

Digital Management and Service Assurance

Service delivery at Tianming Pharmaceutical is structured around a 1-on-1 account manager plus technical engineer support model. Routine technical questions are addressed with reference solutions within 2 hours, while complex technical issues receive a written report within 24 hours. In-stock orders are delivered within 7 to 15 working days, with made-to-order lead times determined by synthesis complexity, workshop scheduling, and raw material availability, and expedited scheduling available for urgent projects. Full batch traceability across raw material receipt, reaction parameters, purification, and testing data is maintained under a GMP-compliant quality assurance system with ISO9001 certification.

Global Reach and a Diversified Customer Base

Tianming Pharmaceutical Group serves more than 2,000 cooperative customers, with domestic demand concentrated in East China, North China, and South China pharmaceutical industry clusters, and international demand across South Asia, the Middle East, and Southeast Asia. According to the source data, pharmaceutical companies represent 56.7% of overall market demand, CRO/CDMO institutions represent 28.6%, biochemical companies 10.8%, trading companies’ distribution share stands at 11.4%, cosmetic raw material companies 9%, and health supplement manufacturers 7.2%. Recognition as a National High-Tech Enterprise, along with provincial Gazelle Enterprise and Specialized and Innovative SME designations across its Shandong Sihuan, Shandong Tianming, and Guangxi Tianming entities, further reflects the company’s standing within China’s pharmaceutical intermediate sector.

Supporting the Broader Ecosystem

Tianming Pharmaceutical’s role extends beyond product supply. The company provides full technical documentation to support customer DMF and CEP filings, collaborates on supplier qualification processes, and supplies impurity standards for quality analysis and method development. Combined with its Jinan 5150 Talent Program designation, its Shandong Province Postdoctoral Innovation Practice Base, and its "New Pharmaceutical Intermediates" Engineering Research Center, these efforts position Tianming Pharmaceutical Group as a partner engaged across the full lifecycle of pharmaceutical intermediate development—from early-stage research through commercial-scale supply.

Home

Tianming Pharmaceutical